These findings uncover a novel mechanism of TEFT action and establish C1R as a potential biomarker and therapeutic target for GBM, particularly for developing combination strategies to overcome treatment resistance in aggressive mesenchymal subtypes. This evidence concerns the gene C1R and glioblastoma.